We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Expands Indication for Bristol-Myers Squibb's PD-1 Inhibitor Opdivo
FDA Expands Indication for Bristol-Myers Squibb's PD-1 Inhibitor Opdivo
Bristol-Myers Squibb's cancer drug Opdivo has gained a new indication as a second line treatment for metastatic squamous non-small cell lung cancer that has progressed after platinum-based chemotherapy.